{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T12:40:04Z","timestamp":1752064804156,"version":"3.41.2"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,9]]},"DOI":"10.7759\/cureus.87589","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T11:58:42Z","timestamp":1752062322000},"source":"Crossref","is-referenced-by-count":0,"title":["Epinastine Eyelid Cream as a Practical Option for Patients With Glaucoma on Multidrug Topical Therapy: A Case Report"],"prefix":"10.7759","author":[{"given":"Yui","family":"Nishijima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-023-00730-z","article-title":"Adherence and persistence to medical therapy in glaucoma: an overview","volume":"12","author":"Quaranta L","year":"2023","unstructured":"Quaranta L, Novella A, Tettamanti M, Pasina L, Weinreb RN, Nobili A. Adherence and persistence to medical therapy in glaucoma: an overview. Ophthalmol Ther. 2023, 12:2227-40. 10.1007\/s40123-023-00730-z","journal-title":"Ophthalmol Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S264926","article-title":"Improving adherence to topical medication in patients with glaucoma","volume":"15","author":"Tapply I","year":"2021","unstructured":"Tapply I, Broadway DC. Improving adherence to topical medication in patients with glaucoma. Patient Prefer Adherence. 2021, 15:1477-89. 10.2147\/PPA.S264926","journal-title":"Patient Prefer Adherence"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13226903","article-title":"Ophthalmic formulations for the treatment of allergic conjunctivitis and their effect on the ocular surface: a review of safety and tolerability assessments in clinical trials","volume":"13","author":"Su\u00e1rez-Cort\u00e9s T","year":"2024","unstructured":"Su\u00e1rez-Cort\u00e9s T, Gonzalo A, Arana E, Guill\u00e9n V, Andollo N. Ophthalmic formulations for the treatment of allergic conjunctivitis and their effect on the ocular surface: a review of safety and tolerability assessments in clinical trials. J Clin Med. 2024, 13:10.3390\/jcm13226903","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/01.icu.0000193079.55240.18","article-title":"The burden of age-related macular degeneration: a value-based analysis","volume":"17","author":"Brown MM","year":"2006","unstructured":"Brown MM, Brown GC, Sharma S, Stein JD, Roth Z, Campanella J, Beauchamp GR. The burden of age-related macular degeneration: a value-based analysis. Curr Opin Ophthalmol. 2006, 17:257-66. 10.1097\/01.icu.0000193079.55240.18","journal-title":"Curr Opin Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-024-01108-9","article-title":"Safety and efficacy of a novel 0.5% epinastine topical eyelid cream in allergic conjunctivitis: a phase 3 trial","volume":"68","author":"Fujishima H","year":"2024","unstructured":"Fujishima H, Shoji J. Safety and efficacy of a novel 0.5% epinastine topical eyelid cream in allergic conjunctivitis: a phase 3 trial. Jpn J Ophthalmol. 2024, 68:651-9. 10.1007\/s10384-024-01108-9","journal-title":"Jpn J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.749858","article-title":"Topical medication therapy for glaucoma and ocular hypertension","volume":"12","author":"Wang T","year":"2021","unstructured":"Wang T, Cao L, Jiang Q, Zhang T. Topical medication therapy for glaucoma and ocular hypertension. Front Pharmacol. 2021, 12:749858. 10.3389\/fphar.2021.749858","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.1955146","article-title":"Sustained release glaucoma therapies: novel modalities for overcoming key treatment barriers associated with topical medications","volume":"54","author":"Belamkar A","year":"2022","unstructured":"Belamkar A, Harris A, Zukerman R, Siesky B, Oddone F, Verticchio Vercellin A, Ciulla TA. Sustained release glaucoma therapies: novel modalities for overcoming key treatment barriers associated with topical medications. Ann Med. 2022, 54:343-58. 10.1080\/07853890.2021.1955146","journal-title":"Ann Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.86792","article-title":"Topical innovation: a report on epinastine eyelid cream for patients with mild atopic keratoconjunctivitis","volume":"17","author":"Mimura T","year":"2025","unstructured":"Mimura T, Fukagawa K. Topical innovation: a report on epinastine eyelid cream for patients with mild atopic keratoconjunctivitis. Cureus. 2025, 17:86792. 10.7759\/cureus.86792","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/388731-epinastine-eyelid-cream-as-a-practical-option-for-patients-with-glaucoma-on-multidrug-topical-therapy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T11:58:43Z","timestamp":1752062323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/388731-epinastine-eyelid-cream-as-a-practical-option-for-patients-with-glaucoma-on-multidrug-topical-therapy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.87589","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,9]]}}}